Memorial Sloan Kettering Cancer Center | Strategic Alliance Partners

Jonathan E. Rosenberg, MD, discusses the phase 3 KEYNOTE-045 trial in advanced urothelial cancer.

James J. Harding, MD, exciting research efforts being made in hepatocellular carcinoma.

James J. Harding, MD, exciting research efforts being made in hepatocellular carcinoma.

Jamie E. Chaft, MD, discusses the emergence of immunotherapy in stage IV lung cancer.

Pembrolizumab combined with trastuzumab and chemotherapy demonstrated promising clinical activity in patients with HER2-positive metastatic esophagogastric cancer.

Jamie E. Chaft, MD, provides insight into IRAEs and immunotherapy restart, considerations for immunotherapy in the pre- and post-operative period, outlines biomarker research in lung cancer, and projects her hopes for the future use of this approach in this space.

Jamie E. Chaft, MD, provides insight into IRAEs and immunotherapy restart, considerations for immunotherapy in the pre- and post-operative period, outlines biomarker research in lung cancer, and projects her hopes for the future use of this approach in this space.

Andrew D. Zelenetz, MD, PhD, discusses progress made in mantle cell lymphoma treatment.

Andrew D. Zelenetz, MD, PhD, discusses progress made in mantle cell lymphoma treatment.

Gopa Iyer, MD, discusses treatment-related adverse events (TRAEs) with erdafitinib (Balversa) in urothelial cancer.

Gopa Iyer, MD, discusses treatment-related adverse events (TRAEs) with erdafitinib (Balversa) in urothelial cancer.

Chung-Han Lee, MD, PhD, discusses second-line treatment options in renal cell carcinoma.

Chung-Han Lee, MD, PhD, discusses second-line treatment options in renal cell carcinoma.

Charles L. Sawyers, MD, discusses the implications of the IMbassador250 trial, other notable presentations delivered at the meeting, and exciting research efforts being made in prostate cancer and beyond.

Charles L. Sawyers, MD, discusses the negative results on the IMbassador250 trial in metastatic castration-resistant prostate cancer.

Ariela Noy, MD, discusses the rationale and design of the phase 2 study of devimistat in patients with aggressive lymphoma.

Yelena Y. Janjigian, MD, discusses data examining surgery plus extensive intraoperative peritoneal lavage versus surgery alone in patients with gastric cancer.

Anthony R. Mato, MD, MSCE, discusses the different research efforts that are being made with immunotherapy in chronic lymphocytic leukemia.

Data from the phase II FIGHT-202 study of pemigatinib in advanced or metastatic FGFR2-positive cholangiocarcinoma have been published as the FDA considers a new drug application for the treatment in this setting.

Yelena Y. Janjigian, MD, discusses results from the phase III JAVELIN Gastric 100 study evaluating avelumab in gastric or gastroesophageal cancer.

Eileen O'Reilly, MD, discusses the potential role of veliparib in pancreatic cancer.

David H. Ilson, MD, PhD, discusses the utility of zolbetuximab in claudin-positive gastric cancers.

Ghassan K. Abou-Alfa, MD, discusses sequencing challenges in metastatic hepatocellular carcinoma.

Chau T. Dang, MD, discusses recent treatment breakthroughs and emerging agents in HER2-positive breast cancer.

Anthony R. Mato, MD, MSCE, discusses the phase III CLL14 trial, which evaluated the efficacy of fixed-duration treatment with venetoclax plus obinutuzumab in patients with chronic lymphocytic leukemia.

Eileen O'Reilly, MD, discusses germline testing in pancreatic cancer.

Ghassan K. Abou-Alfa, MD, discusses the most intriguing updates in hepatocellular carcinoma, anticipated sequencing challenges, and novel modalities on the horizon.

Gopa Iyer, MD, discusses the challenges faced with identifying an optimal screening methodology to select patients with bladder cancer for FGFR inhibitor therapy.

Jae Park, MD, a hematologist oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of CAR T-cell therapies in patients with acute lymphocytic leukemia.

Jonathan E. Rosenberg, MD, medical oncologist, chief, Genitourinary Medical Oncology Service, Memorial Sloan Kettering Cancer Center, discusses the updated results of the phase Ib/II EV-103 trial (NCT03288545) with enfortumab vedotin-ejfv (Padcev) and pembrolizumab (Keytruda) in patients with locally advanced or metastatic urothelial carcinoma.